About
Positions + Comments
News
Members Only
Privacy Policy
Join
Contact

Home / Positions + Comments Archive / Comments to FDA re: Cross-Labeling of Combination Products

Comments OffJuly 8, 2005by adminin

Positions + Comments Archive

Comments to FDA re: Cross-Labeling of Combination Products

Regulatory Algorithm for Combination Product Cross Labeling Issue →← Combination Products Selection Issue Working Group – Key Areas of Difference Among Regulatory Requirements for Drugs, Devices, and Biologics

Like this post?

0

Tweet

More sharing options

About the author

admin

More posts

Popular
Latest

No Popular Posts Found

CPC Comments on FDA’s Statement of Work for the Independent Assessment of Communication Through Product Quality Information Requests During Application Review

CPC Comments on FDA’s Draft Guidance “Computer Software Assurance for Production and Quality System Software”

CPC White Paper to FDA Regarding Validating Specifications

CPC Comments on FDA’s Draft Guidance “Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions”

Recent Posts

CPC Comments on FDA’s Statement of Work for the Independent Assessment of Communication Through Product Quality Information Requests During Application Review
CPC Comments on FDA’s Draft Guidance “Computer Software Assurance for Production and Quality System Software”
CPC White Paper to FDA Regarding Validating Specifications
CPC Comments on FDA’s Draft Guidance “Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions”
CPC Comments on FDA’s “Medical Devices; Quality System Regulation Amendments”

The Combination Products Coalition website is published for informational purposes only; it contains no legal or medical advice whatsoever. Join Our LinkedIn Group